NATIONAL VISION DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds In...

Your unfiltered news center. ®

The world you see depends upon the news you get. ®

HOME

ARTS

RSS

Today's Date: June 3, 2023

New PATHFINDER Study Analysis Demonstrates Efficient Diagnostic Resolution Following Multi-Cancer Early Detection Testing • KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone as First-Line • Promoting Diversity and Equity in Cancer Research, Women Leaders in Oncology® and Vaniam Group Announce Recipients of 2023 Y • Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of SentinelOne, Inc. (S) on Behalf • GRAIL Presents Real-World Experience With The Galleri® Multi-Cancer Early Detection Test At 2023 ASCO Annual Meeting • Bijou Ikli named new CEO by Florida Assisted Living Association • Gilead and Arcus Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival i • Air Canada's Inaugural Amsterdam-Montreal Route Takes Off; Uplifts Sustainable Aviation Fuel in Amsterdam • High Schooler empowers Youth with Nonprofit "Unlimited Potential", raises $100,000 for Sports Medicine Research and Advocacy • LYNPARZA® (olaparib) and IMFINZI® (durvalumab) combination reduced risk of disease progression or death by 37% vs. chemo • UNice Celebrates LGBTQ Pride Month • Statement by the Prime Minister to mark four years since the publication of the final report of the National Inquiry into Missin • Gilead and Arcus Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival i • San Francisco Pride Announces Headliners Hayley Kiyoko and Princess Nokia for 53rd Annual SF Pride Parade & Celebration Feat • Preliminary Ongoing Results with CYT-0851 in Combination with Capecitabine or Gemcitabine in Advanced Solid Tumors Show Early Cl • 56 Trilogy Health Services Communities Earn 2023 AHCA/NCAL Bronze National Quality Award • Statement from Minister Hutchings on progress in support of rural Canadians • Government of Canada releases summary of actions taken to address the safety and wellbeing of Indigenous women, girls and 2SLGBT • Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as a Single Agent After Surgery • Exai Bio Presents New Multi-Cancer Early Detection Data at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

NATIONAL VISION DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Aga

NEW YORK , March 25 /Businesswire/ - Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against National Vision Holdings, Inc. (“National Vision” or the “Company”) (NASDAQ: EYE) in the United States District Court for the Northern District of Georgia on behalf of all persons and entities who purchased or otherwise acquired National Vision securities between May 13, 2021 and May 9, 2022, both dates inclusive (the “Class Period”). Investors have until March 28, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Click here to participate in the action.

According to the Complaint, the Company made false and misleading statements to the market. National Vision faced considerable wage and hiring pressure due to competition and other factors including the COVID-19 pandemic. The Company launched a multi-million-dollar retention plan to avoid mass resignations in 2021. This retention plan was likely to negatively impact the Company’s financial performance in the fourth quarter to a greater extent than it informed investors. Despite the retention plan, the Company faced a startling shortage of optometrists in 2022. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about National Vision, investors suffered damages.

If you purchased or otherwise acquired National Vision shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.